Spyre Therapeutics Inc.
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||||||||||||
| 17.2 | 11.0 | 21.1 | 11.3 | 16.2 | 16.5 | 28.8 | 32.9 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 7.6 | 6.0 | 8.6 | 12.6 | 23.5 | 35.0 | 50.1 | 242.0 | 799.9 | 1,022.0 | 1,435.8 | – | – | – | – | 27.2 | 43.7 | 83.1 | |
| 1.3 | 0.8 | 1.8 | 0.9 | 1.4 | 1.7 | 3.8 | 3.0 | 3.3 | 2.8 | 2.0 | 2.3 | 3.2 | 4.1 | 3.6 | 3.2 | 3.2 | 3.3 | 4.2 | 3.9 | 5.2 | 2.8 | 2.5 | 0.5 | 0.7 | 0.6 | 0.8 | – | – | 2.5 | 9.1 | 2.8 | 4.6 | 2.1 | 2.0 | 2.0 | 2.2 | 3.4 | 5.9 | 6.8 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 6.8 | 0.7 | 2.0 | -2.1 | -6.3 | -153.1 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -18.1% | -37.4% | -20.7% | -40.0% | -29.4% | -29.4% | -16.4% | -13.8% | -14.8% | -17.5% | -17.5% | -21.3% | -22.6% | -27.2% | -47.8% | -16.0% | -18.0% | -17.5% | -14.8% | -11.8% | -10.1% | -22.9% | -39.9% | -198.8% | -162.9% | -272.7% | -261.6% | -156.9% | -164.8% | -21.4% | -8.0% | -14.7% | -10.1% | -14.4% | -17.5% | -16.9% | -15.9% | -6.9% | -4.7% | -2.8% | |
| Margins | ||||||||||||||||||||||||||||||||||||||||
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -46.4% | -132.2% | 66.0% | 15.7% | -73.0% | -25.4% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -410.0% | -473.3% | -498.2% | -512.6% | -535.2% | -531.8% | -516.2% | -490.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -357.6% | -1,246.1% | -1,482.5% | -3,640.2% | -6,793.6% | -17,587.1% | -20,450.8% | -12,567.6% | -15,680.4% | -14,987.7% | -18,543.9% | – | – | – | – | -231.6% | -222.8% | -222.5% | |
| -406.8% | -468.8% | -492.5% | -506.5% | -528.0% | -523.4% | -507.8% | -480.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -358.3% | -1,244.8% | -1,471.8% | -3,598.8% | -6,678.2% | -22,195.4% | -27,934.7% | -17,572.1% | -21,053.5% | -17,848.5% | -20,624.0% | – | – | – | – | -171.5% | -198.3% | -197.7% | |
| -311.1% | -411.7% | -437.1% | -453.6% | -475.9% | -484.9% | -472.1% | -454.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -301.5% | -1,185.4% | -1,400.7% | -3,442.8% | -6,138.7% | -5,495.6% | -8,255.6% | -5,182.1% | -6,405.7% | -15,011.8% | -14,515.1% | – | – | – | – | -187.0% | -205.1% | -230.9% | |
| Returns | ||||||||||||||||||||||||||||||||||||||||
| -29.6% | -34.5% | -40.9% | -39.3% | -47.3% | -54.1% | -66.3% | -43.4% | -56.4% | -65.8% | -45.9% | -62.2% | -89.8% | -130.2% | -186.5% | -54.7% | -58.5% | -57.9% | -65.0% | -55.3% | -66.7% | -78.4% | -116.8% | -104.0% | -126.5% | -166.6% | -231.2% | – | – | -184.1% | -239.2% | -49.7% | -65.6% | -40.2% | -43.3% | -45.4% | -32.7% | -21.7% | -26.7% | -16.2% | |
| -28.0% | -32.4% | -38.2% | -36.6% | -43.4% | -48.6% | -58.5% | -40.0% | -50.4% | -57.0% | -41.5% | -52.8% | -71.6% | -94.1% | -123.2% | -48.1% | -51.2% | -50.1% | -49.1% | -44.8% | -52.7% | -59.9% | -86.6% | -82.0% | -93.3% | -117.8% | -148.3% | -111.9% | -142.1% | -99.1% | -74.7% | -42.6% | -51.0% | -34.2% | -36.7% | -38.4% | -29.5% | -20.0% | -23.5% | -15.3% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | -85 | -25 | -24 | -19 | -12 | -65 | -54 | -90 | -80 | -34 | -24 | -15 | -14 | -37 | -38 | -34 | -35 | -231 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 94.6% | 93.9% | 93.3% | 93.2% | 91.7% | 89.8% | 88.2% | 92.1% | 89.3% | 86.7% | 90.5% | 84.8% | 79.7% | 72.2% | 66.1% | 88.1% | 87.6% | 86.5% | 75.6% | 81.0% | 79.1% | 76.4% | 74.1% | 78.9% | 73.8% | 70.7% | 64.2% | -85.2% | -118.4% | 53.8% | 31.2% | 85.9% | 77.7% | 85.1% | 84.7% | 84.6% | 90.2% | 92.0% | 87.8% | 93.9% | |
| – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| Per Share | ||||||||||||||||||||||||||||||||||||||||
| -37.90 | -46.85 | -43.76 | -43.57 | -39.97 | -42.82 | -43.65 | -38.70 | -40.86 | -44.50 | -46.01 | -47.20 | -54.46 | -60.15 | -60.29 | -39.30 | -32.00 | -34.98 | -30.63 | -25.06 | -25.87 | -33.33 | -27.28 | -26.61 | -22.68 | -32.06 | -20.63 | -71.30 | -68.57 | -15.61 | -9.98 | -4.10 | -4.22 | -4.42 | -3.47 | -3.41 | -2.47 | -2.07 | -2.28 | -2.11 | |
| 9.32 | 9.99 | 8.89 | 8.60 | 7.57 | 8.18 | 8.60 | 8.05 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 7.61 | 2.14 | 1.54 | 0.89 | 0.31 | 0.32 | 0.25 | 0.09 | 0.05 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 1.21 | 1.15 | 1.07 | |
| 127.94 | 135.95 | 106.96 | 110.89 | 84.57 | 79.15 | 65.86 | 89.14 | 72.41 | 67.65 | 100.21 | 75.83 | 60.65 | 46.18 | 32.33 | 71.90 | 54.74 | 60.47 | 47.16 | 45.34 | 38.79 | 42.52 | 23.36 | 25.59 | 17.93 | 19.24 | 8.93 | -54.25 | -57.15 | 8.48 | 4.17 | 8.26 | 6.43 | 11.01 | 8.01 | 7.51 | 7.53 | 9.53 | 8.54 | 13.00 | |
| -28.98 | -41.14 | -38.84 | -39.02 | -36.02 | -39.68 | -40.58 | -36.59 | -35.56 | -32.72 | -35.34 | -36.82 | -43.41 | -51.64 | -56.15 | -37.14 | -31.89 | -34.62 | -29.32 | -20.63 | -20.20 | -27.50 | -22.96 | -25.34 | -21.58 | -30.67 | -18.97 | -17.65 | -20.26 | -4.60 | -3.04 | -3.45 | -2.97 | -3.35 | -2.82 | -2.54 | -2.68 | -2.25 | -2.36 | -2.47 | |
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.